The 36-month beta value for FDMT is also noteworthy at 2.80. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for FDMT is 43.53M, and at present, short sellers hold a 23.76% of that float. The average trading volume of FDMT on August 07, 2024 was 872.06K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
FDMT) stock’s latest price update
4D Molecular Therapeutics Inc (NASDAQ: FDMT)’s stock price has plunge by -1.16relation to previous closing price of 15.50. Nevertheless, the company has seen a -13.59% plunge in its stock price over the last five trading sessions. globenewswire.com reported 2024-08-05 that EMERYVILLE, Calif., Aug. 05, 2024 (GLOBE NEWSWIRE) — 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat large market diseases, today strengthened the Company’s senior management team with the appointments of Dhaval Desai, PharmD, as Chief Development Officer, Christopher Simms as Chief Commercial Officer and Carlos Quezada-Ruiz, M.D., FASRS, as SVP, Therapeutic Area Head, Ophthalmology.
FDMT’s Market Performance
FDMT’s stock has fallen by -13.59% in the past week, with a monthly drop of -32.48% and a quarterly drop of -42.84%. The volatility ratio for the week is 7.12% while the volatility levels for the last 30 days are 11.97% for 4D Molecular Therapeutics Inc The simple moving average for the last 20 days is -20.08% for FDMT stock, with a simple moving average of -29.25% for the last 200 days.
Analysts’ Opinion of FDMT
Many brokerage firms have already submitted their reports for FDMT stocks, with Barclays repeating the rating for FDMT by listing it as a “Overweight.” The predicted price for FDMT in the upcoming period, according to Barclays is $459 based on the research report published on April 15, 2024 of the current year 2024.
Barclays, on the other hand, stated in their research note that they expect to see FDMT reach a price target of $45. The rating they have provided for FDMT stocks is “Overweight” according to the report published on April 15th, 2024.
Goldman gave a rating of “Buy” to FDMT, setting the target price at $81 in the report published on February 07th of the current year.
FDMT Trading at -28.71% from the 50-Day Moving Average
After a stumble in the market that brought FDMT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -57.74% of loss for the given period.
Volatility was left at 11.97%, however, over the last 30 days, the volatility rate increased by 7.12%, as shares sank -33.82% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -38.93% lower at present.
During the last 5 trading sessions, FDMT fell by -13.37%, which changed the moving average for the period of 200-days by +51.78% in comparison to the 20-day moving average, which settled at $18.78. In addition, 4D Molecular Therapeutics Inc saw -24.38% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at FDMT starting from Bizily Scott, who sale 1,750 shares at the price of $27.11 back on Jul 16 ’24. After this action, Bizily Scott now owns 6,781 shares of 4D Molecular Therapeutics Inc, valued at $47,442 using the latest closing price.
Bizily Scott, the Chief Legal Officer of 4D Molecular Therapeutics Inc, sale 1,996 shares at $25.00 during a trade that took place back on Jul 11 ’24, which means that Bizily Scott is holding 6,781 shares at $49,900 based on the most recent closing price.
Stock Fundamentals for FDMT
Current profitability levels for the company are sitting at:
- -5.91 for the present operating margin
- 0.58 for the gross margin
The net margin for 4D Molecular Therapeutics Inc stands at -5.11. The total capital return value is set at -0.2. Equity return is now at value -33.00, with -29.90 for asset returns.
Based on 4D Molecular Therapeutics Inc (FDMT), the company’s capital structure generated 0.02 points at debt to capital in total, while cash flow to debt ratio is standing at -5.43. The debt to equity ratio resting at 0.02. The interest coverage ratio of the stock is -85.62.
Currently, EBITDA for the company is -107.12 million with net debt to EBITDA at 2.25. When we switch over and look at the enterprise to sales, we see a ratio of 25.85. The liquidity ratio also appears to be rather interesting for investors as it stands at 32.65.
Conclusion
In summary, 4D Molecular Therapeutics Inc (FDMT) has had a bad performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
